NSETrading Window3h ago · 25 Sept 2026, 04:17 pm

Trading Window

Akums Drugs and Pharmaceuticals Limited · AKUMS

✦ AI SummaryResults

Akums Drugs and Pharmaceuticals Limited has closed its trading window for insiders due to the upcoming announcement of its un-audited financial results for the quarter ending September 30, 2026.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

NSEAKUMS10_25092026161653_AKUMSTWCLOSURE.pdf

pdf

Download →
View document text
Ref: Akums/Exchange/2026-27/51 September 25, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 544222 Symbol: AKUMS Sub: Closure of Trading Window Respected Sir/Ma’am, This is to inform you that in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the ''Code of Conduct to Regulate, Monitor and Report Trading by designated persons in securities of the Company'', the trading window for dealing in securities of the Company will be closed for all the designated persons (including their immediate relatives) from 1st October, 2026 and shall remain closed till 48 hrs. after the declaration of un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ending 30th September, 2026. Further, the date of meeting of the Board of Directors of the Company to consider and approve the un-audited (Standalone & Consolidated) Financial Results of the Company for the aforesaid periods shall be intimated in due course. This is for your information and records. Thanking You For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer